These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 35743860)
1. Precision Medicine in Cholangiocarcinoma: Past, Present, and Future. Cheng CY; Chen CP; Wu CE Life (Basel); 2022 Jun; 12(6):. PubMed ID: 35743860 [TBL] [Abstract][Full Text] [Related]
2. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements. White K; Anwar AI; Jin K; Bollich V; Kelkar RA; Talbot NC; Klapper RJ; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD Cureus; 2023 Oct; 15(10):e46792. PubMed ID: 37954763 [TBL] [Abstract][Full Text] [Related]
3. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology? Gupta A; Kurzrock R; Adashek JJ Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900367 [TBL] [Abstract][Full Text] [Related]
4. Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management. Gilbert TM; Randle L; Quinn M; McGreevy O; O'leary L; Young R; Diaz-Neito R; Jones RP; Greenhalf B; Goldring C; Fenwick S; Malik H; Palmer DH Eur J Surg Oncol; 2024 Apr; ():108352. PubMed ID: 38653586 [TBL] [Abstract][Full Text] [Related]
5. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Bekaii-Saab TS; Bridgewater J; Normanno N Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504 [TBL] [Abstract][Full Text] [Related]
6. Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments. Valery M; Vasseur D; Fachinetti F; Boilève A; Smolenschi C; Tarabay A; Antoun L; Perret A; Fuerea A; Pudlarz T; Boige V; Hollebecque A; Ducreux M Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760415 [TBL] [Abstract][Full Text] [Related]
7. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma. Lodl E; Ramnaraign B; Sahin I; Wheeler S J Oncol Pharm Pract; 2023 Jul; 29(5):1206-1217. PubMed ID: 37097888 [TBL] [Abstract][Full Text] [Related]
8. Role of molecular genetics in the clinical management of cholangiocarcinoma. Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744 [TBL] [Abstract][Full Text] [Related]
9. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Chong DQ; Zhu AX Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149 [TBL] [Abstract][Full Text] [Related]
10. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion. Storandt MH; Jin Z; Mahipal A Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971 [TBL] [Abstract][Full Text] [Related]
11. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Aitcheson G; Mahipal A; John BV Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096 [No Abstract] [Full Text] [Related]
12. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study. Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644 [TBL] [Abstract][Full Text] [Related]
13. Cholangiocarcinoma Insights: Established Foundations and Cutting-Edge Innovations from Dr. James Cleary's Pioneering Research. Cortiana V; Chorya H; Joshi M; Kannan S; Mahendru D; Vallabhaneni H; Coloma HS; Leyfman Y; Park CH Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339383 [TBL] [Abstract][Full Text] [Related]
14. An evaluation of ivosidenib for the treatment of Tella SH; Mahipal A Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911 [TBL] [Abstract][Full Text] [Related]